Merck & Co., Inc., Dedicates Durham Vaccine Manufacturing Facility in Honor of Merck Scientist Maurice R. Hilleman, Ph.D.

DURHAM, N.C.--(BUSINESS WIRE)--Merck announced today that its Durham, North Carolina, vaccine manufacturing facility has completed start-up activities and is beginning to validate production processes, a major step toward regulatory approval and licensure of the new facility. When licensed, the site will produce key childhood vaccines for measles, mumps, rubella and chickenpox, as well as a vaccine for shingles in older adults. Merck makes 11 of the 17 diseases on the pediatric, adolescent and adult recommended immunization schedules in the United States.
MORE ON THIS TOPIC